Rapid clinical improvement of refractory subacute cutaneous lupus erythematosus with oral tyrosine kinase 2 inhibitor deucravacitinib: A case report
Bernadett Kurz, Irina Ivanova, Konstantin Drexler, Mark Berneburg, Florian Günther, Dennis Niebel
Abstract
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Topics & Concepts
MedicineRefractory (planetary science)Tyrosine-kinase inhibitorDermatologySubacute cutaneous lupus erythematosusLupus erythematosusSystemic lupus erythematosusTyrosine kinaseImmunologyInternal medicineConnective tissue diseaseAntibodyAutoimmune diseaseReceptorAstrobiologyCancerDiseasePhysicsSystemic Lupus Erythematosus ResearchChronic Lymphocytic Leukemia ResearchMonoclonal and Polyclonal Antibodies Research